Company: TELO
Filing Date: 2025-02-04
Form Type: 10-K
Source: 0001493152-25-004872
Chunk: 741

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-02-04
Form: 10-K
Item: Item 2
Chunk 741
---

The
Company has the authority to issue 400,000,000 shares of capital stock, consisting of 300,000,000 shares of Common Stock and 100,000,000
shares of undesignated preferred stock, whose rights and privileges will be defined by the Board of Directors when a series of preferred
stock is designated.

Reverse
Stock Split

Effective
December 11, 2023, the Company completed a reverse stock split of its outstanding common stock upon the filing of the Company’s
Second Amended and Restated Articles of Incorporation with the Florida Secretary of State. No fractional shares were or will be issued
in connection with the reverse stock split, and all such fractional shares resulting from the reverse stock split were and will be rounded
up to the nearest whole number. The shares issuable upon the exercise of our outstanding warrants, and the exercise price of such warrants,
have been adjusted to reflect the reverse stock split. Unless otherwise noted, all share and per share information in this Report retrospectively
reflects the reverse stock split.

Common
Stock

During the year ended December 31, 2023, the Company conducted a private
placement offering in which 268,025 shares were issued for a total of $0.9 million in net proceeds to the Company.

On
February 13, 2024, the Company closed its initial public offering consisting of 1,000,000 shares at a price of $7.00 per
share for approximately $7.0 million in gross proceeds. After deducting the underwriting commission and other offering expenses
totaling $1.2 million, the net proceeds to the Company were $5.8 million (the “IPO”).

On
December 9, 2024, Starwood Trust, a related party, entered into a stock purchase agreement with the Company to purchase 142,857
shares of unregistered common stock at $7
a share for a total of $1.0
million in proceeds to the Company.

During the year ended December 31, 2024, deferred
offering costs from December 31, 2023 of $303,281 and offering costs of $863,744 incurred in 2024 were charged against additional paid
in capital.

    F-13

Telomir
                                            Pharmaceuticals, Inc.

notes
to the financial statements

DECEMBER
31, 2024 and  2023

Warrants

In